In last trading session, Ginkgo Bioworks Holdings Inc. (NYSE:DNA) saw 24.62 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.87 trading at -$0.07 or -2.38% at ring of the bell on the day assigns it a market valuation of $4.77B. That closing price of DNA’s stock is at a discount of -452.61% from its 52-week high price of $15.86 and is indicating a premium of 27.18% from its 52-week low price of $2.09. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 20.54 million shares which gives us an average trading volume of 25.33 million if we extend that period to 3-months.
For Ginkgo Bioworks Holdings Inc. (DNA), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.04 in the current quarter.
Ginkgo Bioworks Holdings Inc. (NYSE:DNA) trade information
Upright in the red during last session for losing -2.38%, in the last five days DNA remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $2.87 price level, adding 15.59% to its value on the day. Ginkgo Bioworks Holdings Inc.’s shares saw a change of -65.46% in year-to-date performance and have moved -6.51% in past 5-day. Ginkgo Bioworks Holdings Inc. (NYSE:DNA) showed a performance of 6.69% in past 30-days. Number of shares sold short was 144.64 million shares which calculate 5.41 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $7.48 to the stock, which implies a rise of 61.63% to its current value. Analysts have been projecting $3.00 as a low price target for the stock while placing it at a high target of $14.50. It follows that stock’s current price would drop -405.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -4.53% for stock’s current value.
Ginkgo Bioworks Holdings Inc. (DNA) estimates and forecasts
Statistics highlight that Ginkgo Bioworks Holdings Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -10.03% of value to its shares in past 6 months, showing an annual growth rate of 20.00% while that of industry is 1.70. Apart from that, the company came raising its revenue forecast for fiscal year 2022. This year revenue growth is estimated to rise 22.10% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $77.63 million for the same. And 6 analysts are in estimates of company making revenue of $66.72 million in the next quarter that will end on Sep 2022.
Ginkgo Bioworks Holdings Inc. is more likely to be releasing its next quarterly report on November 15 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Ginkgo Bioworks Holdings Inc. (NYSE:DNA)’s Major holders
Insiders are in possession of 6.53% of company’s total shares while institution are holding 77.37 percent of that, with stock having share float percentage of 82.78%. Investors also watch the number of corporate investors in a company very closely, which is 77.37% institutions for Ginkgo Bioworks Holdings Inc. that are currently holding shares of the company. Baillie Gifford and Company is the top institutional holder at DNA for having 167.75 million shares of worth $676.04 million. And as of Mar 30, 2022, it was holding 15.34% of the company’s outstanding shares.
The second largest institutional holder is General Atlantic, L.P., which was holding about 90.81 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 8.30% of outstanding shares, having a total worth of $365.97 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 58.96 million shares of worth $140.32 million or 5.39% of the total outstanding shares. The later fund manager was in possession of 21.58 million shares on Jun 29, 2022, making its stake of worth around $51.35 million in the company or a holder of 1.97% of company’s stock.